The European Society for Medical Oncology (ESMO), together with Oxford Journals, and the Japanese Society of Medical Oncology (JSMO) are pleased to announce a new collaboration which will result in ESMOs official journal Annals of Oncology becoming the official scientific publication for the Japanese society.
Annals of Oncology is fully owned by ESMO and is published by Oxford Journals. From 2008, the journal will be endorsed by JSMO and all members of the Japanese society will have online access to the journal, increasing the distribution to approximately 15,000. Annals of Oncology will take on two additional Associate Editors and 12 new Editorial Board members from Japanese institutions. To mark the beginning of this new collaboration, the first issue of 2008 will focus on Japanese authors.
"This is great news for JSMO and for the journal," commented Prof. David Kerr, Editor-in-Chief of Annals of Oncology and ESMO President-Elect 2008-2009. "Japanese groups have made significant contributions to the journal in recent years, and I am proud that JSMO has now chosen Annals as their official journal."
He continued, "The success of Annals of Oncology is based on quality of service, content, and access. These are values that have always been key to ESMO and that are also shared by JSMO. This collaboration will help us to build on the success of the journal. I truly hope that we can be an example of how, by working together, using science to inform our decisions, and considering the real needs of our populations, we can shape the future of oncology for the better."
Dr Nagahiro Saijo, President of JSMO, added, We are delighted to have Annals of Oncology as JSMOs official journal, and that all our members will have access to its top quality research. Through this partnership we hope to strengthen the ties between Japanese and European researchers and to increase the number of Japanese papers published in the journal. We believe that the JSMO Associate Editors and Editorial Board members will help to encourage the exchange of opinions and research within the global oncology community.
|Contact: Vanessa Pavinato|
European Society for Medical Oncology